Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
William Blair Maintains Krystal Biotech(KRYS.US) With Buy Rating
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $196
Promising Clinical Data and Platform Potential Drive Buy Rating for Krystal Biotech
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
El Gato99 : $240 by early November, Jamie delivers again.